RWP
CRNX

RWA Wealth Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

RWA Wealth Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Hold
9,271
– – ﹤0.01% 537
2026
Q1 		$337K Buy
9,271
+2,425
+35% +$108K ﹤0.01% 520
2025
Q4 		$319K Buy
6,846
+1,150
+20% +$51.2K ﹤0.01% 511
2025
Q3 		$237K Buy
+5,696
New +$182K ﹤0.01% 572
2025
Q1 		– Sell
-5,696
Closed -$291K – 549
2024
Q4 		$291K Hold
5,696
– – ﹤0.01% 493
2024
Q3 		$291K Hold
5,696
– – ﹤0.01% 482
2024
Q2 		$255K Hold
5,696
– – ﹤0.01% 486
2024
Q1 		$267K Hold
5,696
– – ﹤0.01% 478
2023
Q4 		$203K Buy
+5,696
New +$175K ﹤0.01% 507

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RWA Wealth Partners's CRNX Position: Q2 2026 in Review

RWA Wealth Partners held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 9,271 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #537.

RWA Wealth Partners first reported a position in CRNX in Q4 2023 and has held it in 9 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • RWA Wealth Partners held 9,271 shares of Crinetics Pharmaceuticals worth $347K as of Q2 2026.
  • RWA Wealth Partners left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of RWA Wealth Partners's portfolio in Q2 2026, its #537 holding.
  • RWA Wealth Partners first reported a position in Crinetics Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on RWA Wealth Partners's 13F filing for Q2 2026, filed 7 Aug 2026.